TransMedics Group (NASDAQ:TMDX) Price Target Raised to $142.00 at Canaccord Genuity Group

TransMedics Group (NASDAQ:TMDX - Get Free Report) had its target price increased by analysts at Canaccord Genuity Group from $129.00 to $142.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Canaccord Genuity Group's price target suggests a potential upside of 25.02% from the company's current price.

A number of other equities research analysts also recently weighed in on the company. Oppenheimer raised their price objective on TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research report on Tuesday, June 17th. Piper Sandler reaffirmed an "overweight" rating and set a $145.00 price objective (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research report on Tuesday, June 17th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $129.88.

TransMedics Group Stock Up 0.2%

Shares of TMDX traded up $0.26 during midday trading on Tuesday, reaching $113.58. 200,746 shares of the stock were exchanged, compared to its average volume of 1,374,517. TransMedics Group has a 52 week low of $55.00 and a 52 week high of $177.37. The company has a current ratio of 9.10, a quick ratio of 8.32 and a debt-to-equity ratio of 1.92. The company's 50 day moving average is $126.78 and its two-hundred day moving average is $91.56. The company has a market capitalization of $3.84 billion, a P/E ratio of 83.68 and a beta of 2.06.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.29 by $0.41. TransMedics Group had a return on equity of 21.88% and a net margin of 10.03%. The company had revenue of $143.54 million for the quarter, compared to the consensus estimate of $123.39 million. During the same quarter last year, the company earned $0.35 earnings per share. The firm's revenue for the quarter was up 48.2% compared to the same quarter last year. On average, sell-side analysts anticipate that TransMedics Group will post 1 earnings per share for the current year.

Insiders Place Their Bets

In other TransMedics Group news, Director Edward M. Basile sold 5,000 shares of the firm's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $126.45, for a total value of $632,250.00. Following the completion of the sale, the director owned 2,866 shares of the company's stock, valued at approximately $362,405.70. This trade represents a 63.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David Weill sold 732 shares of the firm's stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $123.88, for a total value of $90,680.16. Following the completion of the sale, the director directly owned 12,134 shares of the company's stock, valued at approximately $1,503,159.92. This represents a 5.69% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 12,418 shares of company stock valued at $1,512,613. 7.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of TransMedics Group by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company's stock worth $226,700,000 after purchasing an additional 40,860 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of TransMedics Group by 244.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company's stock worth $209,448,000 after purchasing an additional 2,209,996 shares during the last quarter. FIL Ltd raised its position in TransMedics Group by 28.0% during the fourth quarter. FIL Ltd now owns 1,000,358 shares of the company's stock valued at $62,372,000 after acquiring an additional 218,961 shares in the last quarter. Braidwell LP purchased a new position in TransMedics Group during the fourth quarter valued at approximately $57,493,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in TransMedics Group by 16.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 903,086 shares of the company's stock valued at $56,307,000 after acquiring an additional 128,474 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.